Brian Varnum - 13 Apr 2022 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Reporting relationship: President and CEO
Issuer ticker: ARMP
Reported as of: 13 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Apr 2022, 15:46:48 UTC
Prior SEC filing: 03 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ Todd R. Patrick, attorney-in-fact

Key filing fact

Brian Varnum filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 15 Apr 2022.

Key facts

This page summarizes Brian Varnum's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Apr 2022, 15:46.

Change

Previous filing in this sequence was filed on 03 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARMP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +240,000
Change %
Price: $0.000000
Shares after: 240,000
Date: 13 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 240,000
Exercise price: $5.11
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant.